Skip to main content

Table 4 Time to tumor progression (TTP) by dose cohort

From: Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer

Dose cohort

1 mg/kg

(n = 3)

3 mg/kg

(n = 6)

9 mg/kg

(n = 6)

16 mg/kg

(n = 7)

Median TTP (days)

39

39

40

44

25th-75th percentile

33-46

38-80

31-41

36-80

Range

33-46

35-117

28-119

35-106

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us